I
Ines Lakhal-Naouar
Researcher at Center for Biologics Evaluation and Research
Publications - 4
Citations - 121
Ines Lakhal-Naouar is an academic researcher from Center for Biologics Evaluation and Research. The author has contributed to research in topics: Mutant & Wild type. The author has an hindex of 4, co-authored 4 publications receiving 112 citations.
Papers
More filters
Journal ArticleDOI
Immunity to Visceral Leishmaniasis Using Genetically Defined Live-Attenuated Parasites
Angamuthu Selvapandiyan,Ranadhir Dey,Sreenivas Gannavaram,Ines Lakhal-Naouar,Robert Duncan,Poonam Salotra,Hira L. Nakhasi +6 more
TL;DR: Development and characteristics of genetically altered, live-attenuated Leishmania donovani parasites and their possible use as vaccine candidates against VL are discussed.
Journal ArticleDOI
Leishmania donovani Argininosuccinate Synthase Is an Active Enzyme Associated with Parasite Pathogenesis
Ines Lakhal-Naouar,Armando Jardim,Rona Strasser,Shen Luo,Yukiko Kozakai,Hira L. Nakhasi,Robert Duncan +6 more
TL;DR: It is suggested that LdASS is an active enzyme, with unique localization and essential for parasite survival and growth in the mammalian host and could be further explored as a potential drug target.
Journal ArticleDOI
Deletion of Ubiquitin Fold Modifier Protein Ufm1 Processing Peptidase Ufsp in L. donovani Abolishes Ufm1 Processing and Alters Pathogenesis
TL;DR: Biochemical analysis of L. donovani Ufsp showed that this protein possesses the Ufm1 processing activity using sensitive FRET based activity probes, indicating the essential nature of this protease for Leishmania pathogenesis.
Journal ArticleDOI
Identification and characterization of genes involved in leishmania pathogenesis: the potential for drug target selection.
Robert Duncan,Sreenivas Gannavaram,Ranadhir Dey,Alain Debrabant,Ines Lakhal-Naouar,Hira L. Nakhasi +5 more
TL;DR: Identifying and characterizing Leishmania donovani genes and the proteins they encode for their role in pathogenesis can reveal the value of this approach for finding new drug targets, and how disruption of those pathways could point to additional drug targets.